Nordic Life Science asked Göran Forsberg, CEO of Cantargia, about Cantargia’s future plans and his reactions to the Nobel Prizes.
Congratulations on the listing on the main market Nasdaq Stockholm. What does this mean for the company?
“Thank you! This means that the company will receive more exposure and attention. It also means that new investors (institutes and specialist funds) focusing on the main market will start following us and have the possibility to invest in Cantargia.”
What opportunities do you have on the market for antibody based pharmaceuticals?
“We develop a new antibody targeting a molecule of importance for cancer. In this development, we have come the furthest. No one else has reached this far. We have also approved patents around treatments against this target molecule. In general, the use of antibodies in cancer treatments is strongly increasing. Several antibodies are today selling for between 5 to 10 billion USD. We have seen that our antibody CAN04 has a profile, and hence a potential, that fits well with what will be sought after in the future. This means that if we obtain positive results from our clinical studies we will have a good chance to enter the markets where we today are in the development stages (foremost lung cancer and pancreatic cancer where there is a great need for new pharmaceuticals).”
What’s next for Cantargia?
“In the short run our upcoming phase I results and the transition to phase IIa in our clinical trial CANFOUR is of great importance (update: positive clinical data was presented in the end of October). During 2019 the implementation of the phase IIa study, which is relatively large (80-90 patients), is a major event.”
What are your reactions to the Nobel Prize in Physiology or Medicine?
“We are therefore very happy that the Nobel Prize has been awarded to two scientists who have demonstrated the value of using the body’s own immune system to fight cancer.”
“To manipulate the immune system to treat cancer patients is probably the hottest research area today and this is where Cantargia also is contributing. We are therefore very happy that the Nobel Prize has been awarded to two scientists who have demonstrated the value of using the body’s own immune system to fight cancer. We continue to strive to make future cancer therapies even better.”
What are your reactions to the Prize in Chemistry?
“These technologies have been a part of the Cantargia toolbox and will also in the future continue to be important to further develop and broaden our project portfolio.”